Biological treatment 2026 II
Original notice title
Biologická léčba 2026 II
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
No procurement documents analyzed; eligibility criteria, required documents, and technical specifications are unknown.
Lots 2 and 3 have no titles or descriptions, making it difficult to assess scope and prepare bids.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- CZK 9.2M estimated value
- Supplies contract
- 3 lots
- Duration 12 MONTH
- Ongoing supply of medicinal products for biological treatment.
- Contract divided into 3 lots based on active substances.
Show full summary
This tender by Krajská nemocnice T. Bati, a. s. in Czechia is for the supply of antineoplastic agents (biologics) divided into 3 lots based on active substances. The overall estimated value is 9,210,289.77 CZK. The procedure is open, with award based on lowest price. Only lot 1 (Everolimus) has a specific title; lots 2 and 3 lack titles and descriptions. Procurement documents were not analyzed, so eligibility and required documents are unknown. Submission is electronic, in Czech only, with a deadline of 2026-07-13.
Risks
No procurement documents analyzed; eligibility criteria, required documents, and technical specifications are unknown.
Lots 2 and 3 have no titles or descriptions, making it difficult to assess scope and prepare bids.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Open procedure.
Administrative
- Electronic submission required.
- Submission languages: Czech only.
Requirements may be incomplete.
Award Criteria
Lot 1
Lot 2
Lot 3
Buyer
Name
Krajská nemocnice T. Bati, a. s.
Location
Zlín, CZE
Buyer profile
Identifier
27661989
Lots (3)
LOT-0001
I. Everolimus (ATC L01EG02)
Supply of Everolimus, a biological medicinal product. Duration 12 months.
CZK 2M
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Value note
Show original TED data
Original TED description
Předmětem veřejné zakázky jsou průběžné dodávky léčivých přípravků pro biologickou léčbu v rozsahu dle potřeb zadavatele. Veřejná zakázka je rozdělena dle účinných látek na 3 části. Bližší specifikace je uvedena v příloze č. 3.1 – 3.3 zadávací dokumentace - Cenová nabídka.
LOT-0002
II. Axitinib (ATC L01EK01)
Supply of an antineoplastic agent (active substance not specified in available data). Duration 12 months.
CZK 3M
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Value note
Show original TED data
Original TED description
Předmětem veřejné zakázky jsou průběžné dodávky léčivých přípravků pro biologickou léčbu v rozsahu dle potřeb zadavatele. Veřejná zakázka je rozdělena dle účinných látek na 3 části. Bližší specifikace je uvedena v příloze č. 3.1 – 3.3 zadávací dokumentace - Cenová nabídka.
LOT-0003
III. Denosumab (ATC M05BX04)
Supply of an antineoplastic agent (active substance not specified in available data). Duration 12 months.
CZK 4.3M
Estimated value
Location
Duration
Category
Selection criteria
Deadline
Award details
Value note
Show original TED data
Original TED description
Předmětem veřejné zakázky jsou průběžné dodávky léčivých přípravků pro biologickou léčbu v rozsahu dle potřeb zadavatele. Veřejná zakázka je rozdělena dle účinných látek na 3 části. Bližší specifikace je uvedena v příloze č. 3.1 – 3.3 zadávací dokumentace - Cenová nabídka.
Procurement Details
- Publication date
- 11 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- Czech
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 403784-2026
- Source notice ID
- c6ad729a-8ae5-4eac-9ebf-9331a20c23bf
Documents (2)
Similar tenders
Poland – Antineoplastic agents – Dostawa produktów leczniczych i wyrobów medycznych do Wojskowego Instytutu Medycznego – PIB
Poland – Antineoplastic agents – Leki onkologiczne i sprzęt pomocniczy
Romania – Antineoplastic agents – achizitia de medicamente utilizate in tratamentul pacientilor beneficiari ai Programului Programului national de oncologie-Subprogramul de tratament medicamentos al bolnavilor cu afectiuni oncologice (adulti si copii), Programul national de oncologie medicamente COST-VOLUM
Poland – Pharmaceutical products – Przetarg uzupełniający na dostawę do WCSKJ produktów leczniczych stosowanych w programach lekowych i chemioterapii
Czechia – Antineoplastic agents – Léčivé přípravky s obsahem antineoplastik
Romania – General anti-infectives for systemic use and vaccines – Achizitie Medicamente 1 - 2026
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
40 / 100
Risk factors
No procurement documents analyzed; eligibility criteria, required documents, and technical specifications are unknown.
Lots 2 and 3 have no titles or descriptions, making it difficult to assess scope and prepare bids.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications